Financial Performance and Subsidiaries Revenue

R&D CAPABILITIES R&D Expense (* in million) NATCO 2,500 14.0% 12% 12.0% R&D capabilities demonstrated by its complex and niche product filings in formulations and API segments 2,000 9.3% 8.7% 9.1% 7.8% 1,500 10.0% 8% 8.0% 2,267 6.0% 1,000 1,976 1,950 1,665 1,656 1,596 Two research facilities with capabilities across synthetic chemistry, nano pharmaceuticals, new drug discovery and cell biology 4.0% 500 2.0% 0.0% FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 R&D Expense R&D Expense% Specialised R&D laboratories in two research facilities Talented Pool of Scientists: 465(1) 8% 22% 70% 9% 4% 27% FINISHED DOSAGE FORMULATIONS (FDF) (2) ACTIVE PHARMACEUTICAL INGREDIENTS (API) 5% ■ AR & D ■ CR & D ■ Masters ■ Ph.D. Others 30% 25% ■ FR & D ■NDDS 19 Para IV filings in pipeline 55 Cumulative DMFs filed ■RA ■Others BREAKDOWN OF SCIENTISTS FY numbers have been prepared under Ind AS (1) As of March 31, 2023 2) As of March 31, 2023. Does not include integrated DMFS filed with ANDAS 7 approved Para IV (either tentative or final) 44 active DMFS (2 11

View entire presentation